Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Sales (2016 - 2025)

Historic Return on Sales for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to 0.78%.

  • Coherus Oncology's Return on Sales fell 53100.0% to 0.78% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.95%, marking a year-over-year increase of 4000.0%. This contributed to the annual value of 0.11% for FY2024, which is 10300.0% up from last year.
  • As of Q3 2025, Coherus Oncology's Return on Sales stood at 0.78%, which was down 53100.0% from 33.41% recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Return on Sales ranged from a high of 74.05% in Q1 2024 and a low of 2.33% during Q1 2023
  • Moreover, its 5-year median value for Return on Sales was 0.62% (2021), whereas its average is 5.49%.
  • Its Return on Sales has fluctuated over the past 5 years, first soared by 763900bps in 2024, then tumbled by -752600bps in 2025.
  • Quarter analysis of 5 years shows Coherus Oncology's Return on Sales stood at 0.62% in 2021, then plummeted by -108bps to 1.3% in 2022, then surged by 33bps to 0.87% in 2023, then surged by 192bps to 0.8% in 2024, then decreased by -3bps to 0.78% in 2025.
  • Its last three reported values are 0.78% in Q3 2025, 33.41% for Q2 2025, and 1.21% during Q1 2025.